873077-70-4

Basic information

• Product Name: N,N-Didesethyl Sunitinib Hydrochloride
• Synonyms: N-(2-Aminoethyl)-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide Hydrochloride;N,N-Didesethyl Sunitinib Hydrochloride
• CAS NO: 873077-70-4
• Molecular Formula: C18H20ClFN4O2
• Molecular Weight: 342.37
• Product Categories: Pharmaceuticals;Tyrosine Kinase Inhibitors;Pfizer compounds;Various Metabolites and Impurities;Intermediates & Fine Chemicals;Metabolites & Impurities
• Mol File: 873077-70-4.mol
• Article Data: 4

Chemical Properties

• Melting Point: >3000C (dec.)
• Appearance: /
• Storage Temp.: -20°C Freezer
• CAS DataBase Reference: N,N-Didesethyl Sunitinib Hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-Didesethyl Sunitinib Hydrochloride(873077-70-4)
• EPA Substance Registry System: N,N-Didesethyl Sunitinib Hydrochloride(873077-70-4)

Safety Data

• Hazardous Substances Data: 873077-70-4(Hazardous Substances Data)

Usage

Chemical Properties

Yellow Solid

Uses

A metabolite of Sunitinib

InChI:InChI=1/C18H19FN4O2.ClH/c1-9-15(22-10(2)16(9)18(25)21-6-5-20)8-13-12-7-11(19)3-4-14(12)23-17(13)24;/h3-4,7-8,22H,5-6,20H2,1-2H3,(H,21,25)(H,23,24);1H/b13-8-;

Upstream product

• 443-69-6 5-fluoro-1H-indole-2,3-dione 
• 1158560-66-7 (Z)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carbonyl chloride 
• 356068-93-4 5-((Z)-(5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 
• 253870-02-9 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 
• 56341-41-4 5-fluoroindol-2(3H)-one 
• 1227960-76-0 tert-butyl (Z)-(2-(5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamido)ethyl)carbamate 

Relevant articles and documents

CONJUGATES OF AMPK INHIBITORS AND PROTAC DEGRADERS AND RELATED USES

The present disclosure relates to compounds of Formula (I): T-L-D, stereoisomers thereof, prodrugs thereof, and pharmaceutically acceptable salts thereof, wherein T is an AMPK inhibiting moiety; L is a linking moiety; and D is a PROTAC degrading moiety. The present disclosure also relates to uses of the compounds, e.g., to inhibit AMP-Activated protein kinase (AMPK), degrading AMPK protein, and/or treat cancer in a subject.

AMP-ACTIVATED PROTEIN KINASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME

The present disclosure relates to compounds of Formula (I): (I); stereoisomers thereof, prodrugs thereof, and pharmaceutically acceptable salts thereof. The present disclosure also relates to uses of the compounds, e.g., to inhibit AMP-Activated protein kinase (AMPK) and treat cancer in a subject.